Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape

In this podcast episode, Charles Rudin, MD, PhD, and Mark A. Socinski, MD, discuss current gaps and clinical needs for patients with relapsed ES-SCLC, and the evolving role of B7-H3–directed antibody–drug conjugates in the management of patients with ES-SCLC, including:

Clinical needs for relapsed ES-SCLCScientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLCADCs, T-cell engagers, chemotherapy-based approaches, maintenance strategies, and ongoing clinical trials for ES-SCLCRecent efficacy and safety data for B7-H3–directed ADCs in ES-SCLC, including I-DXdPersonalization of care of patients with SCLC, including patient-specific factors influencing treatmentCase discussion of a patient with ES-SCLC requiring optimal next best treatmentImportance of enrolling patients in ongoing trials of investigational agents for patients with ES-SCLC

Presenters:
Charles Rudin, MD, PhD
Cancer Center Director
Memorial Sloan Kettering Cancer Center
New York, New York

Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Orlando, Florida

Link to full program:
https://bit.ly/3UBEeYz

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.